COVID-19: Anatomy, Physiology, Pharmacology and Treatment | Association of American Physicians and Surgeons

Content Source/Owner:

Association of American Physicians and Surgeons

https://www.youtube.com/user/aapsonline/

https://aapsonline.org/

1 hr 40 min

Summary:

June 3, 2021 webinar led by Harpal Mangat, MD

Meeting Notes and Time marker (credit: Mark Steudlein https://www.youtube.com/channel/UCc4Vb0UInP62sQt_RqkqMNg/)

1. Intro – 0:00

2. Dr Harpal Mangat – 4:28

a. ACE Fundamentals – 8:00

i. Avoid Ibuprofen

b. Bronchial Evidence –11:28

c. JAK STAT Pathway – 12:56

i. Medications, preventing cytokine storm

1. Famotidine 2. Barictinab 3. Apoquel (dogs)

d. Coronaviruses – 14:14

e. Covid Habitat 15:36

f. Covid-19 – 15:57

i. Not a natural virus

g. Treatment Key Slide – 18:17

i. Early treatment is key to mortality

h. Objective Phase 0 Treatment – 24:00

i. Prevent Covid getting to lungs

1. Nasal rinses 2. Bevespi/Breztri 3. Ipratropium 4. Ciclesonide, Budnesonide

i. Phase Zero Treatment – 26:10

i. Same as above

1. Sotrovimab

j. Intracellular Covid Life Cycle – 28:03

i. Goal 1 – Prevent ACE2 activation

1. Regeneron-cov, Bamlanivimab+Etasvinmab, Sotrovimb

ii. Goal 2 – Shut down Bradykinin storm

1. Bendryl (diphenylhydramine)

k. Objective Phase 1 Treatment – 32:00

i. 2-6 days to get viral load to zero

l. Criteria for Antibody Usage – 33:08

m. Phase 2 Treatment – 33:50

i. Goal 1 – Prevent RNA Replication

1. hydroxychloroquine 2. Remdesevir 3. [avoid] Favipiravir

n. Phase 3 Treatment – 40:27

i. Goal 1 – Inhibit Cytokine signal

1. Pepsid (Famotidine, Baricitinab)

o. Use Case 1 and Treatment – 41:54

p. Use Case 2 and Treatment – 46:40

q. Phase 4 Treatment – 54:00

i. Goal 1 – Reduce Cytokine Storm

1. Toclizumab 2. Eliquis

r. Recap of early treatment – 55:25

i. Results ii. Contacts

s. Additional Use Cases – 57:29

t. Multidrug treatment study – 1:16:20

u. Conclusions – 1:17:45

v. Questions – 1:19:00

https://youtu.be/ZqVIlj2NlRA

————–